Foghorn Therapeutics Reports Q3'26 Financials, Advancing IBD and Hematological Malignancy Programs
Foghorn Therapeutics reported strong cash positions and progress in clinical programs for IBD and multiple myeloma, forecasting first-in-human trials by late 2027. The biotech anticipates an FDA IND filing in 2027, supported by a robust balance sheet.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed